Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is presented as the preferred 2026 biotech investment after FY2025 revenue rose 9.9% to $36.7B, net income reached $7.7B, and free cash flow totaled $8.1B. CRISPR Therapeutics offers gene-editing upside through CASGEVY but generated only $3.5M of FY2025 revenue, down about 90% year over year, while posting a $581.6M net loss and negative $345.9M free cash flow. Amgen's stability, raised outlook, dividend, and diversified growth drivers are weighed against risks from drug-price regulation, biosimilars, litigation, and high leverage; CRISPR remains dependent on Vertex, continued CASGEVY execution, funding, and clinical success.

Analysis

The relevant AMGN debate is not stability versus innovation; it is whether pipeline-led growth can outrun a looming mix of Medicare price resets, biosimilar erosion, and elevated financing costs. AMGN's leverage makes incremental operating misses disproportionately damaging to equity free cash flow, while its wholesale-channel concentration gives MCK, COR, and CAH potential working-capital and pricing leverage in any reimbursement disruption. Over 6-18 months, the key valuation catalyst is evidence that newer franchises replace erosion on an organic basis rather than through further debt-funded business development.

CRSP should be valued as a cash runway plus a series of development and launch options, not on P/E or sales multiples. Commercial uptake for an autologous therapy is constrained by treatment-center throughput, conditioning capacity, payer authorization, and patient willingness—not simply regulatory approval—so revenue can remain lumpy even if clinical demand is strong. The more direct public-market read-through is VRTX, which controls commercialization economics; however, the supplied ticker "VERX" is Veeva, not Vertex, and should not be used as the partner exposure.

Consensus may underappreciate the asymmetry in each name: AMGN can de-rate before reported revenue weakens if net-price pressure or debt-service assumptions deteriorate, whereas CRSP can rally sharply on operational milestones without near-term earnings inflection. The article's CRSP revenue and commercialization assertions are internally difficult to reconcile, making the stated financial comparison insufficiently reliable for a directional trade. Near term, this is primarily an earnings/transcript-monitoring setup rather than a catalyst created by the article itself.

Key Decisions for Investors

• Maintain a neutral-to-underweight AMGN stance versus diversified large-cap pharma until the next earnings update quantifies net-price, biosimilar, and debt-reduction trajectories; initiate an underweight only if management lowers growth guidance or free-cash-flow conversion misses expectations. Thesis is falsified by sustained organic growth and accelerated deleveraging that preserve the current valuation multiple.
• Use VRTX—not VERX—as the listed commercial proxy for CASGEVY execution. Add only after quarterly disclosures show rising treated-patient volume and improving center throughput; a failure of sequential uptake over the next 1-2 quarters would argue against the commercialization thesis despite favorable clinical demand.
• Keep CRSP on a catalyst watch list rather than establishing a core long. Reassess after verified cash runway, quarterly operating-burn, royalty/revenue recognition, and pipeline timelines are available; an equity raise or burn materially above plan is the principal 6-12 month downside trigger.
• For a relative-value expression after data validation, prefer long VRTX / short CRSP in equal dollar amounts: VRTX captures product economics and has diversified cash flows, while CRSP retains financing, IP, and pipeline-concentration risk. Close the spread if CRSP demonstrates materially faster-than-expected independent pipeline value creation or if VRTX guides to launch economics below expectations.